Jefferies Raises Price Target on Orexigen Therapeutics (OREX), Maintains Buy Rating
Tweet Send to a Friend
Jefferies keeps their Buy rating on Orexigen Therapeutics (NASDAQ: OREX) while they raise their price target to $17 from $12 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
